Despoina Vasilakou, Thomas Karagiannis, Eleni Athanasiadou, Maria Mainou, Aris Liakos, Eleni Bekiari, Maria Sarigianni, David R Matthews, Apostolos Tsapas. Ann Intern Med 2013
Times Cited: 547
Times Cited: 547
Michaël J B van Baar, Charlotte C van Ruiten, Marcel H A Muskiet, Liselotte van Bloemendaal, Richard G IJzerman, Daniël H van Raalte. Diabetes Care 2018
Times Cited: 86
Times Cited: 86
List of shared articles
Times cited
Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial.
Charlotte C van Ruiten, Mark M Smits, Megan D Kok, Erik H Serné, Daniël H van Raalte, Mark H H Kramer, Max Nieuwdorp, Richard G IJzerman. Cardiovasc Diabetol 2022
Charlotte C van Ruiten, Mark M Smits, Megan D Kok, Erik H Serné, Daniël H van Raalte, Mark H H Kramer, Max Nieuwdorp, Richard G IJzerman. Cardiovasc Diabetol 2022
Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors.
Mohammad Shafi Kuchay, Khalid Jamal Farooqui, Sunil Kumar Mishra, Ambrish Mithal. Adv Exp Med Biol 2021
Mohammad Shafi Kuchay, Khalid Jamal Farooqui, Sunil Kumar Mishra, Ambrish Mithal. Adv Exp Med Biol 2021
Medical management of resistant hypertension: the role of sodium-glucose cotransporter 2 inhibitors (SGLT2i).
Muhannad Alqudsi, Juan Carlos Q Velez, Jose Navarrete. Curr Opin Cardiol 2021
Muhannad Alqudsi, Juan Carlos Q Velez, Jose Navarrete. Curr Opin Cardiol 2021
Impact of Sodium-Glucose Co-Transporter 2 Inhibitors on Cardiac Protection.
Victor Chien-Chia Wu, Yan-Rong Li, Chao-Yung Wang. Int J Mol Sci 2021
Victor Chien-Chia Wu, Yan-Rong Li, Chao-Yung Wang. Int J Mol Sci 2021
Adding Sodium-Glucose Co-Transporter 2 Inhibitors to Sulfonylureas and Risk of Hypoglycemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Meng Jiang, Qiaoshu Liu, Tiejian Jiang, Paul Nizigiyimana, Minxiang Lei. Front Endocrinol (Lausanne) 2021
Meng Jiang, Qiaoshu Liu, Tiejian Jiang, Paul Nizigiyimana, Minxiang Lei. Front Endocrinol (Lausanne) 2021
Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure.
Rudolf A de Boer, Julio Núñez, Plamen Kozlovski, Yi Wang, Pieter Proot, Deborah Keefe. Br J Clin Pharmacol 2020
Rudolf A de Boer, Julio Núñez, Plamen Kozlovski, Yi Wang, Pieter Proot, Deborah Keefe. Br J Clin Pharmacol 2020
Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity.
Harold E Bays, Plamen Kozlovski, Qing Shao, Pieter Proot, Deborah Keefe. Obesity (Silver Spring) 2020
Harold E Bays, Plamen Kozlovski, Qing Shao, Pieter Proot, Deborah Keefe. Obesity (Silver Spring) 2020
Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY.
Jinnie J Rhee, Meg J Jardine, Glenn M Chertow, Kenneth W Mahaffey. Diabetes Obes Metab 2020
Jinnie J Rhee, Meg J Jardine, Glenn M Chertow, Kenneth W Mahaffey. Diabetes Obes Metab 2020